MHMiguel A. Hermida

Miguel A. Hermida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miguel A. Hermida has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeted therapy for LIMD1 -deficient non-small cell lung cancer subtypes

    by Kathryn Davidson, Paul Grevitt, Maria F. Contreras G., Katherine S. Bridge, Miguel Hermida, Kunal M. Shah, Faraz K Mardakheh, Mark Stubbs, Paul A. Clarke, Rosemary Burke, et al.

    An early event in lung oncogenesis is loss of the tumour suppressor gene LIMD1 (LIM domains containing 1); this encodes a scaffold protein, which suppresses tumourigenesis via a number of different mechanisms. Approximately 45% of non-small cell lung cancers (NSCLC) are deficient in LIMD1 1 , yet this subtype of NSCLC has been overlooked in preclinical and clinical investigations. Defining therapeutic targets in these LIMD1 loss-of-function patients is difficult due to a lack of ‘druggable’ targets, thus alternative approaches are required. To this end, we performed the first drug repurposing screen to identify compounds that confer synthetic lethality with LIMD1 loss in NSCLC cells. PF-477736 was shown to selectively target LIMD1 deficient cells in vitro through inhibition of multiple kinases, inducing cell death via apoptosis. Furthermore, PF-477736 was effective in treating LIMD1 −/− tumors in subcutaneous xenograft models, with no significant effect in LIMD1 +/+ cells. We have identified a novel drug tool with significant preclinical characterization that serves as an excellent candidate to explore and define LIMD1-deficient cancers as a new therapeutic subgroup of critical unmet need. Significance Statement: Here we provide the first proof-of-concept data validating the scope for development of a targeted therapy against the non-small cell lung cancers (NSCLC) subtypes deficient in expression of the LIMD1 tumor suppressor gene. Approximately 45% of NSCLC are deficient in LIMD1 1 representing at least 1.2 million lung cancer patients worldwide; yet this subtype has been ignored in preclinical and clinical investigations with no targeted therapies available. This seminal study applied synthetic lethality drug screening to target the loss/reduction of LIMD1 in lung cancer and normal cell lines, identifying and validating the multi-kinase inhibitor PF-477736 as a selectively cytotoxic compound towards LIMD1 deficient cells. This study provides rationale for further investigation into targeting LIMD1 loss in lung cancer, thereby addressing a critical unmet need for therapeutic approached to targeting LIMD1-deficent cancer subtypes.

  • Three dimensional in vitro models of cancer: Bioprinting multilineage glioblastoma models

    by Miguel A. Hermida, Jothi Dinesh Kumar, Daniela Schwarz, Keith G. Laverty, Alberto Di Bartolo, Marcus Ardron, Mihails Bogomolnijs, Anne Clavreul, Paul M. Brennan, Ulrich K. Wiegand, et al.


  • Open Access

    A HIF–LIMD1 negative feedback mechanism mitigates the pro‐tumorigenic effects of hypoxia

    by Daniel E Foxler, Katherine S Bridge, John G Foster, Paul Grevitt, Sean Curry, Kunal M Shah, Kathryn M Davidson, Ai Nagano, Emanuela Gadaleta, Hefin I Rhys, et al.

    The adaptive cellular response to low oxygen tensions is mediated by the hypoxia‐inducible factors (HIFs), a family of heterodimeric transcription factors composed of HIF‐α and HIF‐β subunits. Prolonged HIF expression is a key contributor to cellular transformation, tumorigenesis and metastasis. As such, HIF degradation under hypoxic conditions is an essential homeostatic and tumour‐suppressive mechanism. LIMD1 complexes with PHD2 and VHL in physiological oxygen levels (normoxia) to facilitate proteasomal degradation of the HIF‐α subunit. Here, we identify LIMD1 as a HIF‐1 target gene, which mediates a previously uncharacterised, negative regulatory feedback mechanism for hypoxic HIF‐α degradation by modulating PHD2‐LIMD1‐VHL complex formation. Hypoxic induction of LIMD1 expression results in increased HIF‐α protein degradation, inhibiting HIF‐1 target gene expression, tumour growth and vascularisation. Furthermore, we report that copy number variation at the LIMD1 locus occurs in 47.1% of lung adenocarcinoma patients, correlates with enhanced expression of a HIF target gene signature and is a negative prognostic indicator. Taken together, our data open a new field of research into the aetiology, diagnosis and prognosis of LIMD1‐negative lung cancers. Synopsis This study identifies the tumour suppressor LIMD1 as a facilitator of an adaptive cellular response to hypoxia. Under hypoxic conditions, LIMD1 expression is induced, facilitating degradation of HIF, limiting HIF transcriptional activity and mitigating its pro‐tumorigenic effects. The LIMD1 promoter contains a hypoxia responsive element (HRE) and its expression is induced under hypoxic conditions driving increased HIF degradation via the PHD/VHL axis. HIF protein stability and transcriptional activity are reduced under chronic hypoxic conditions by LIMD1. Aberration of the LIMD1‐dependent hypoxic negative feedback loop causes larger and more vascularised tumours to grow in vivo. LIMD1 is lost in 47% of adenocarcinoma driving a hypoxic gene signature that serves as a negative prognostic indicator.